Hamps Bio IPO is a fixed-price offering valued at ₹6.22 crore. The IPO consists entirely of a fresh issue of 12.2 lakh equity shares. The subscription period for Hamps Bio IPO starts on December 13, 2024, and ends on December 17, 2024. Allotment is expected to be finalised on December 18, 2024, with a tentative listing date set for December 20, 2024, on the BSE SME platform.
The issue price for Hamps Bio IPO is set at ₹51 per share, with a minimum lot size of 2,000 shares. Retail investors need to invest a minimum of ₹1,02,000, while high-net-worth individuals (HNIs) require a minimum investment of ₹2,04,000, corresponding to two lots (4,000 shares).
Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. serves as the book-running lead manager for the IPO. Bigshare Services Pvt. Ltd. is the registrar, ensuring smooth allotment and compliance processes. Pure Broking is the designated market maker for this issue.
Industry Outlook
- India is the world's largest provider of generic drugs and supplies 20% of global generic exports. The domestic pharmaceutical industry is expected to grow from $65 billion in 2024 to $130 billion by 2030, with a CAGR of 9.43%.
- Indian biotechnology, a significant contributor to the pharma industry, is projected to reach $150 billion by 2025. The biosimilars segment alone is estimated to grow at a CAGR of 22%, contributing $12 billion by 2025, equating to 20% of the overall pharma market in India.
Hamps Bio IPO Objectives
The company plans to utilise the funds for the following purposes:
- Funds will be used to purchase plant and machinery to enhance production capabilities for the FMCG segment.
- A portion of the proceeds will focus on improving brand awareness and market visibility for the company’s products.
- The remaining funds will be allocated for general corporate purposes.
About Hamps Bio Limited
Hamps Bio Limited is a prominent name in the ethical marketing and distribution of pharmaceutical formulation products and freeze-dried and frozen products. Established in 2007, the company operates under two distinct segments: pharmaceutical formulations and freeze-dried and frozen products.
The pharmaceutical division offers a wide range of products, including tablets, syrups, capsules, injectables, and powders, marketed under the “Hamps” brand. These products cater to diverse therapeutic needs such as pediatric care, pain relief, and nutritional supplements, targeting medical professionals like orthopedists, physicians, and gynecologists.
The company’s freeze-dried and frozen product division, launched in 2017, operates under the “FzyEzy” brand. It specialises in processing fruits, vegetables, herbs, and flowers using advanced freeze-drying technology. The business model includes both B2B and B2C approaches, offering white-label solutions to customers and selling products directly through a robust distribution network and e-commerce platforms like Amazon and Flipkart.
Hamps Bio Limited boasts a strong domestic presence, with products available in over 50 distribution networks across 8 states. Its international reach spans 6 countries. The company’s marketing team connects with over 8,000 doctors and medical stores monthly, achieving significant sales milestones.
How To Check the Allotment Status of the Hamps Bio IPO ?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
How to apply for the Hamps Bio IPO online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Hamps Bio IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
Contact Details of Hamps Bio Limited
Registered office: 2900/112, GIDC, Near Atul Limited, Ankelshwar, Bharuch–393 002, Gujarat, India.
Phone:+91 8000006663
E-mail: info@hampsbio.com
Hamps Bio IPO Reservation
|
Investor Category |
Shares Offered |
|
Anchor Investor Shares Offered |
- |
|
Market Maker Shares Offered |
62,000 (5.08%) |
|
Other Shares Offered |
5,79,000 (47.46%) |
|
Retail Shares Offered |
5,79,000 (47.46%) |
|
Total Shares Offered |
12,20,001 (100%) |
Hamps Bio IPO Lot Size
|
Application |
Lots |
Shares |
Amount |
|
Retail (Min) |
1 |
2,000 |
₹1,02,000 |
|
Retail (Max) |
1 |
2,000 |
₹1,02,000 |
|
S-HNI (Min) |
2 |
4,000 |
₹2,04,000 |
Hamps Bio IPO Promoter Holding
The company is promoted by Herrik Shah, Shrenik Shah, Pallavi Shah, Mitali Shah, Herrik Shah HUF and Shrenik Shah HUF.
|
Share Holding Pre-Issue |
100.00% |
|
Share Holding Post Issue |
71.99% |
Key Performance Indicators for Hamps Bio Limited
The market capitalisation of Hamps Bio stands at ₹22.22 crore, as of March 31, 2024.
|
KPI |
Values |
|
ROE |
21.14% |
|
ROCE |
18.31% |
|
Debt/Equity |
0.31 |
|
RoNW |
14.84% |
|
P/BV |
2.96 |
|
PAT Margin (%) |
7.73 |
Hamps Bio IPO Prospectus
Hamps Bio IPO Registrar and Lead Managers
Hamps Bio IPO Book Running and Lead Managers
Marwadi Chandarana Intermediaries Brokers Pvt. Ltd.
Registrar for Hamps Bio IPO
Bigshare Services Pvt Ltd
- Contact Number: +91-22-6263 8200
- Email: ipo@bigshareonline.com
Website: Link Intime India Private Ltd Registrar
Financial Performance of Hamps Bio Limited
| Particulars | Year ended March 31, 2024 | Year ended March 31, 2023 |
|---|---|---|
| Revenue from Operation (in ₹ lakh) | 647.53 | 557.81 |
| Profit for the year (in ₹ lakh) | 50.07 | 35.90 |
| Net Worth (in ₹ lakh) | 337.42 | 136.30 |
| Earnings per share in ₹ | 1.76 | 1.50 |
| EBITDA (in ₹ lakh) | 117.72 | 86.63 |
| Return on Equity (%) | 21.14 | 30.31 |
| Debt Equity Ratio (x) | 0.31 | 1.27 |
Know before investing
Strengths
7Expert leadership and skilled team drive strategic business growth.
Expansive distribution network enhances market reach and customer access.
Diverse product portfolio caters to varied market and industry demands.
Strong domestic and global presence ensures wider market opportunities.
Recognised brands build customer trust and enhance market visibility.
Quality assurance systems ensure superior products and customer satisfaction.
Investments in capacity and markets meet increasing product demand.
Risks
7Dependence on third-party manufacturers without long-term agreements increases vulnerability.
Top 10 contract manufacturers contributed 41.03% of purchases as of October 2024.
Single manufacturing facility concentration in Gujarat exposes operational risks.
Failure to renew licenses may disrupt operations and impact growth.
Noncompliance with stringent pharmaceutical standards risks penalties and liabilities.
Product liability claims could harm reputation and financial stability.
Counterfeit or substandard products in the market may damage brand trust.
